TRCT
ACET icon

Tower Research Capital (TRC)’s Adicet Bio ACET Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.68K Buy
1,421
+349
+33% +$2.61K ﹤0.01% 3917
2025
Q4 		$9.03K Buy
1,072
+760
+244% +$8.4K ﹤0.01% 3924
2025
Q3 		$4.04K Sell
312
-1,504
-83% -$17.7K ﹤0.01% 4411
2025
Q2 		$17.7K Buy
1,816
+673
+59% +$7.1K ﹤0.01% 3745
2025
Q1 		$13.8K Buy
+1,143
New +$16.3K ﹤0.01% 3331
2024
Q3 		– Sell
-2,215
Closed -$42.9K – 5685
2024
Q2 		$42.9K Buy
2,215
+2,031
+1,104% +$54.4K ﹤0.01% 3216
2024
Q1 		$6.92K Sell
184
-573
-76% -$23.7K ﹤0.01% 4294
2023
Q4 		$22.9K Buy
757
+75
+11% +$1.64K ﹤0.01% 3563
2023
Q3 		$14.9K Sell
682
-25
-4% -$883 ﹤0.01% 3646
2023
Q2 		$27.5K Buy
707
+525
+288% +$46.3K ﹤0.01% 3105
2023
Q1 		$17K Buy
182
+97
+114% +$12.2K ﹤0.01% 3606
2022
Q4 		$13K Sell
85
-34
-29% -$8.48K ﹤0.01% 3566
2022
Q3 		$27K Buy
119
+29
+32% +$7.36K ﹤0.01% 3675
2022
Q2 		$21K Sell
90
-374
-81% -$82.1K ﹤0.01% 3718
2022
Q1 		$148K Buy
464
+371
+399% +$85.3K ﹤0.01% 1952
2021
Q4 		$26K Buy
93
+21
+29% +$3.6K ﹤0.01% 3372
2021
Q3 		$9K Sell
72
-99
-58% -$12.3K ﹤0.01% 4401
2021
Q2 		$28K Buy
171
+16
+10% +$3.26K ﹤0.01% 3556
2021
Q1 		$32K Buy
155
+108
+230% +$24.8K ﹤0.01% 3508
2020
Q4 		$11K Sell
47
-98
-68% -$20.1K ﹤0.01% 4240
2020
Q3 		$28K Buy
145
+111
+326% +$28.1K ﹤0.01% 3745
2020
Q2 		$8K Buy
+34
New +$6.68K ﹤0.01% 4089
2020
Q1 		– Sell
-20
Closed -$3K – 2956
2019
Q4 		$3K Buy
20
+16
+400% +$8.1K ﹤0.01% 2866
2019
Q3 		$4K Buy
+4
New +$4.47K ﹤0.01% 3381
2019
Q2 		– Sell
-61
Closed -$46K – 3587
2019
Q1 		$46K Buy
61
+49
+408% +$44.5K ﹤0.01% 1800
2018
Q4 		$12K Sell
12
-8
-40% -$10.5K ﹤0.01% 2301
2018
Q3 		$35K Buy
20
+10
+100% +$13K ﹤0.01% 1976
2018
Q2 		$10K Sell
10
-24
-71% -$25.8K ﹤0.01% 2767
2018
Q1 		$36K Buy
+34
New +$62.4K ﹤0.01% 1860

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tower Research Capital (TRC)'s ACET Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Adicet Bio (ACET) stake by 33% in Q1 2026, buying an estimated $2.61K and bringing the position to 1,421 shares worth $9.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3917.

Tower Research Capital (TRC) first reported a position in ACET in Q1 2018 and has held it in 29 quarters since. The position peaked at $148K in Q1 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Tower Research Capital (TRC) held 1,421 shares of Adicet Bio worth $9.68K as of Q1 2026.
  • Tower Research Capital (TRC) bought 349 Adicet Bio shares in Q1 2026, an estimated $2.61K.
  • Adicet Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3917 holding.
  • Tower Research Capital (TRC) first reported a position in Adicet Bio in Q1 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Adicet Bio position peaked at $148K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.